Evidence map›Paper›PMID 28770105›Full record

ArticleThe journal of pathology. Clinical research2017

Multi-parametric profiling of renal cell, colorectal, and ovarian cancer identifies tumour-type-specific stroma phenotypes and a novel vascular biomarker.

Sara Corvigno, Magnus Frödin, G Bea A Wisman, Hans W Nijman, Ate Gj Van der Zee, Karin Jirström, Björn Nodin, Ina Hrynchyk, David Edler, Peter Ragnhammar and 4 more

Open access · goldAbstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 3 countries.

Sara CorvignoDepartment of Oncology-PathologyKarolinska InstitutetStockholmSweden.ORCID 0000-0001-5458-2243
Magnus FrödinDepartment of Oncology-PathologyKarolinska InstitutetStockholmSweden.
G Bea A WismanDepartment of Gynecologic OncologyUniversity of Groningen, University Medical Center GroningenGroningenThe Netherlands.
Hans W NijmanDepartment of Gynecologic OncologyUniversity of Groningen, University Medical Center GroningenGroningenThe Netherlands.
Ate Gj Van der ZeeDepartment of Gynecologic OncologyUniversity of Groningen, University Medical Center GroningenGroningenThe Netherlands.
Karin JirströmDepartment of Clinical Sciences, Division of Oncology and PathologyLund UniversityLundSweden.
Björn NodinDepartment of Clinical Sciences, Division of Oncology and PathologyLund UniversityLundSweden.
Ina HrynchykCity Clinical Pathologoanatomic BureauMinskBelarus.
David EdlerDepartment of Molecular Medicine and SurgeryKarolinska University Hospital SolnaStockholmSweden.
Peter RagnhammarDepartment of Oncology-PathologyKarolinska InstitutetStockholmSweden.
Martin JohanssonDepartment of Laboratory MedicineSkånes UniversitetssjukhusMalmö.ORCID 0000-0001-8510-3102
Hanna DahlstrandDepartment of Oncology-PathologyKarolinska InstitutetStockholmSweden.
Artur MezheyeuskiDepartment of Oncology-PathologyKarolinska InstitutetStockholmSweden.
Arne ÖstmanDepartment of Oncology-PathologyKarolinska InstitutetStockholmSweden.
Karolinska Institutet · SEUniversity Medical Center Groningen · NLLund University · SE9th City Clinical Hospital · BYKarolinska University Hospital · SESkåne University Hospital · SEUppsala University · SEUppsala University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel set of integrated procedures for quantification of fibroblast-rich stroma and vascular characteristics has recently been presented allowing discovery of novel perivascular and stromal biomarkers in colorectal, renal cell, and ovarian cancer. In the present study, data obtained through these procedures from clinically well-annotated collections of these three tumour types have been used to address two novel questions. First, data have been used to investigate if the three tumour types demonstrate significant differences regarding features such as vessel diameter, vessel density, and perivascular marker expression. Second, analyses of the cohorts have been used to explore the prognostic significance of a novel vascular metric, 'vessel distance inter-quartile range (IQR)' that describes intra-case heterogeneity regarding vessel distribution. The comparisons between the three tumour types demonstrated a set of significant differences. Vessel density of renal cell cancer was statistically significantly higher than in colorectal and ovarian cancer. Vessel diameter was statistically significantly higher in ovarian cancer. Concerning perivascular status, colorectal cancer displayed significantly higher levels of perivascular PDGFR-β expression than the other two tumour types. Intra-case heterogeneity of perivascular PDGFR-β expression was also higher in colorectal cancer. Notably, these fibroblast-dominated stroma phenotypes matched previously described experimental tumour stroma characteristics, which have been linked to differential sensitivity to anti-VEGF drugs. High 'vessel distance IQR' was significantly associated with poor survival in both renal cell cancer and colorectal cancer. In renal cell cancer, this characteristic also acted as an independent prognostic marker according to multivariate analyses including standard clinico-pathological characteristics. Explorative subset analyses indicated particularly strong prognostic significance of 'vessel distance IQR' in T stage 4 of this cancer type. Together, these analyses identified tumour-type-specific vascular-stroma phenotypes of possible functional significance, and suggest 'vessel distance IQR' as a novel prognostic biomarker.

Indexed as

colorectal cancerovarian cancerPDGFR‐βpericytesrenal cell cancersurvivaltumour microenvironmentvessels

Identifiers

PMID28770105
PMCPMC5527322
OpenAlexW2625134101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.